![Figure 1 from Comparison of Prasugrel and Ticagrelor Antiplatelet Effects in Korean Patients Presenting With ST-Segment Elevation Myocardial Infarction. | Semantic Scholar Figure 1 from Comparison of Prasugrel and Ticagrelor Antiplatelet Effects in Korean Patients Presenting With ST-Segment Elevation Myocardial Infarction. | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/fb588a93cdb2e141130a337c611bf3d2fc680490/2-Figure1-1.png)
Figure 1 from Comparison of Prasugrel and Ticagrelor Antiplatelet Effects in Korean Patients Presenting With ST-Segment Elevation Myocardial Infarction. | Semantic Scholar
![Impact of Escalating Loading Dose Regimens of Ticagrelor in Patients With ST-Segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention: Results of a Prospective Randomized Pharmacokinetic and Pharmacodynamic ... Impact of Escalating Loading Dose Regimens of Ticagrelor in Patients With ST-Segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention: Results of a Prospective Randomized Pharmacokinetic and Pharmacodynamic ...](https://ars.els-cdn.com/content/image/1-s2.0-S1936879815009966-gr1.jpg)
Impact of Escalating Loading Dose Regimens of Ticagrelor in Patients With ST-Segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention: Results of a Prospective Randomized Pharmacokinetic and Pharmacodynamic ...
![Ticagrelor (Brilinta) for Secondary Prevention of Thrombotic Events Following Acute Coronary Syndrome | AAFP Ticagrelor (Brilinta) for Secondary Prevention of Thrombotic Events Following Acute Coronary Syndrome | AAFP](https://www.aafp.org/content/dam/brand/aafp/pubs/afp/issues/2013/1215/p821-ut1.gif)
Ticagrelor (Brilinta) for Secondary Prevention of Thrombotic Events Following Acute Coronary Syndrome | AAFP
![Low-dose ticagrelor yields an antiplatelet efficacy similar to that of standard-dose ticagrelor in healthy subjects: an open-label randomized controlled trial | Scientific Reports Low-dose ticagrelor yields an antiplatelet efficacy similar to that of standard-dose ticagrelor in healthy subjects: an open-label randomized controlled trial | Scientific Reports](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fsrep31838/MediaObjects/41598_2016_Article_BFsrep31838_Fig1_HTML.jpg)
Low-dose ticagrelor yields an antiplatelet efficacy similar to that of standard-dose ticagrelor in healthy subjects: an open-label randomized controlled trial | Scientific Reports
![Dr. Sheila Sahni on Twitter: "Algorithm for switching between oral P2Y12 inhibitors in the acute and chronic setting. (For the Figure: LD = loading dose; MD = maintenance dose) Source: 2017 ESC Dr. Sheila Sahni on Twitter: "Algorithm for switching between oral P2Y12 inhibitors in the acute and chronic setting. (For the Figure: LD = loading dose; MD = maintenance dose) Source: 2017 ESC](https://pbs.twimg.com/media/DolJmHqUwAEInrl.jpg:large)
Dr. Sheila Sahni on Twitter: "Algorithm for switching between oral P2Y12 inhibitors in the acute and chronic setting. (For the Figure: LD = loading dose; MD = maintenance dose) Source: 2017 ESC
![PDF) Switching Ticagrelor to 600 mg or 300 mg Clopidogrel Loading Bridge in Patients with Unstable Angina PDF) Switching Ticagrelor to 600 mg or 300 mg Clopidogrel Loading Bridge in Patients with Unstable Angina](https://www.researchgate.net/profile/Sinem-Cakal/publication/352070870/figure/fig1/AS:1030440756465664@1622687629909/Algorithm-for-switching-between-oral-P2Y12-inhibitors-in-the-acute-setting-LD-loading_Q320.jpg)
PDF) Switching Ticagrelor to 600 mg or 300 mg Clopidogrel Loading Bridge in Patients with Unstable Angina
![Half‐Dose (45 mg Twice Daily) Ticagrelor Versus Clopidogrel in Neuroendovascular Dual Antiplatelet Therapy: A Single‐Center Cohort Study | Stroke: Vascular and Interventional Neurology Half‐Dose (45 mg Twice Daily) Ticagrelor Versus Clopidogrel in Neuroendovascular Dual Antiplatelet Therapy: A Single‐Center Cohort Study | Stroke: Vascular and Interventional Neurology](https://www.ahajournals.org/cms/asset/72916ca7-0636-4808-8981-1a926a234009/svi212369-gra-0001.png)
Half‐Dose (45 mg Twice Daily) Ticagrelor Versus Clopidogrel in Neuroendovascular Dual Antiplatelet Therapy: A Single‐Center Cohort Study | Stroke: Vascular and Interventional Neurology
![JCM | Free Full-Text | Pharmacodynamics and Outcomes of a De-Escalation Strategy with Half-Dose Prasugrel or Ticagrelor in East Asians Patients with Acute Coronary Syndrome: Results from HOPE-TAILOR Trial JCM | Free Full-Text | Pharmacodynamics and Outcomes of a De-Escalation Strategy with Half-Dose Prasugrel or Ticagrelor in East Asians Patients with Acute Coronary Syndrome: Results from HOPE-TAILOR Trial](https://www.mdpi.com/jcm/jcm-10-02699/article_deploy/html/images/jcm-10-02699-g001-550.jpg)